BOSTON, MA--(Marketwire - January 24, 2011) - Polaris Venture Partners today announced that it is relocating its successful Dogpatch Labs Cambridge and will open new space in the Microsoft New England Research & Development Center (N.E.R.D), located at One Cambridge Center. In its new location, Dogpatch will continue to provide entrepreneurs with space, connectivity and "open-sourced" collaboration through introductions, mentoring, frequent industry events, community interaction and public open houses.
"Among the goals we had in creating Dogpatch Labs was to tap into and support the vibrant start-up ecosystem in the region, and its success to date has led to deeper connections and stronger collaboration with others in the community," said Dave Barrett, General Partner of Polaris Venture Partners. "Microsoft, among others, has been an especially important Polaris collaborator and they've done a great job of building an innovation culture in Kendall Square. While we're not formally affiliated with them or other tenants in the N.E.R.D space, we all share a deep commitment to identifying breakthrough entrepreneurs and doing whatever we can to nurture them. Our common goal is to help support great innovation in this region."
Dogpatch Labs Cambridge now houses more than 55 entrepreneurs, and the new space will enable it to expand the roster of residents in 2011. The move is expected to take place by the end of Jan. Earlier this month, Polaris Venture Partners announced that Gus Weber, a distinguished N.E.R.D alum, joined Dogpatch Labs Cambridge as its new entrepreneur in residence (EIR).
About Polaris Venture Partners
Polaris Venture Partners is a partnership of experienced investors, operating executives and entrepreneurs. The firm's mission is to identify, invest in and partner with seed, early stage, and middle-market businesses with exceptional promise and help them grow into market-leading companies. Polaris invests in businesses across a number of markets including technology, digital media, consumer, enertech and life sciences. Polaris-backed successes in life sciences include: Adimab, Adnexus (sold to BMS), Advanced Inhalation Research (sold to Alkermes), Alimera (ALIM), Alnylam Pharmaceuticals (ALNY), Asthmatx (sold to Boston Scientific) Glycofi (sold to Merck), Momenta Pharmaceuticals (MNTA) and Ironwood (IRWD). Polaris-backed successes in technology and consumer include: Akamai Technologies (AKAM), Allaire, Art.com, Athlete's Performance, Automattic (WordPress), e-Rewards, LogMeIn (LOGM), LegalZoom, LivingProof, MarkMonitor, Powersoft, Solidworks, TechTarget (TTGT) and Quantcast. For more on the firm, its mission and its portfolio companies: http://www.polarisventures.com.
Contact Information:
Media Contact
Scott Bauman
Greenough Communications
617-275-6518